Equity Profile

UTHR

United Therapeutics Corporation

Health CareBiotechnology$23.6B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

United Therapeutics Corporation is a biotechnology company focused on developing innovative therapies for patients with chronic and life-threatening conditions. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, particularly in the treatment of pulmonary arterial hypertension and other serious diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

UTHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.12%

Avg Stock Reaction

+0.87%

Last Quarter Recap

In Q1 2026, United Therapeutics reported an EPS of $5.82, falling short of the estimated $6.73, resulting in a -13.57% surprise. Despite the miss, the stock rose 4.29% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for United Therapeutics are mixed, with some analysts concerned about the recent earnings miss while others remain optimistic about the company's long-term growth potential.

Bull Case

The bull case hinges on strong pipeline developments and potential new product approvals that could drive significant revenue growth.

Bear Case

Conversely, the bear case centers around continued earnings misses and potential delays in product launches, which could dampen investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on the drug pipeline and any upcoming product launches?

These updates will be critical in determining the company's growth trajectory and investor confidence.

How is the company addressing the recent earnings miss and what measures are being taken to improve profitability?

Understanding management's strategy to enhance financial performance will be key for investors assessing future risks.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of new drug approvals and pipeline advancements, which could significantly boost revenue.

Supporting Evidence

The recent earnings miss may not fully reflect the long-term growth potential driven by the drug pipeline.

Options pricing suggests a larger move than historical averages, indicating that investors are anticipating significant news.

Insider selling could be misinterpreted; it may not reflect a lack of confidence in the company's future prospects.

Key Risk

If new product approvals exceed expectations, it could shift the narrative and lead to a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will likely hinge on the company's ability to meet or exceed expectations in these critical areas.

Bull Confirmed If

Positive updates on the drug pipeline with at least one new product approval or significant trial results.

Bear Confirmed If

Continued earnings misses or negative updates on product development timelines.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±6.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.2% while UTHR has averaged ±6.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.0%

Calls (5K)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$84.9M

147,285 sh

4 insiders

Net

$84.9M

Net selling

Most Active Insiders· 148 open-market trades

Chairperson & CEOROTHBLATT MARTINE A
$54.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If United Therapeutics beats expectations, history suggests the stock could rise around 3.01%, confirming bullish sentiment.

In-Line / Cautious

An in-line report may lead to a muted response as investors await clearer guidance on future growth.

Miss

A miss could result in a decline of about 2.71%, reflecting ongoing concerns about profitability and growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product approvals.
2Management's strategy for addressing the recent earnings miss.
3Comments on revenue growth and market expansion plans.
4Insights into competitive positioning and market trends.
5Any changes in guidance or expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help gauge how well the company is managing its costs and revenue.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market share and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

UTHR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+0.12%

Avg Stock Reaction

+0.87%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for United Therapeutics are mixed, with some analysts concerned about the recent earnings miss while others remain optimistic about the company's long-term growth potential.

Bull Case

The bull case hinges on strong pipeline developments and potential new product approvals that could drive significant revenue growth.

Bear Case

Conversely, the bear case centers around continued earnings misses and potential delays in product launches, which could dampen investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on the drug pipeline and any upcoming product launches?

These updates will be critical in determining the company's growth trajectory and investor confidence.

How is the company addressing the recent earnings miss and what measures are being taken to improve profitability?

Understanding management's strategy to enhance financial performance will be key for investors assessing future risks.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of new drug approvals and pipeline advancements, which could significantly boost revenue.

Supporting Evidence

The recent earnings miss may not fully reflect the long-term growth potential driven by the drug pipeline.

Options pricing suggests a larger move than historical averages, indicating that investors are anticipating significant news.

Insider selling could be misinterpreted; it may not reflect a lack of confidence in the company's future prospects.

Key Risk

If new product approvals exceed expectations, it could shift the narrative and lead to a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will likely hinge on the company's ability to meet or exceed expectations in these critical areas.

Bull Confirmed If

Positive updates on the drug pipeline with at least one new product approval or significant trial results.

Bear Confirmed If

Continued earnings misses or negative updates on product development timelines.

Pre-Earnings Positioning

Options Market

Implied Move

±13.2%

Historical Avg

±6.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±13.2% while UTHR has averaged ±6.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.0%

Calls (5K)P/C Ratio: 1.00Puts (200)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$84.9M

147,285 sh

4 insiders

Net

$84.9M

Net selling

Most Active Insiders· 148 open-market trades

Chairperson & CEOROTHBLATT MARTINE A
$54.8M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If United Therapeutics beats expectations, history suggests the stock could rise around 3.01%, confirming bullish sentiment.

In-Line / Cautious

An in-line report may lead to a muted response as investors await clearer guidance on future growth.

Miss

A miss could result in a decline of about 2.71%, reflecting ongoing concerns about profitability and growth.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product approvals.
2Management's strategy for addressing the recent earnings miss.
3Comments on revenue growth and market expansion plans.
4Insights into competitive positioning and market trends.
5Any changes in guidance or expectations for the upcoming quarters.